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Abstract
The T cell response is an integral and essential part of the host immune response to acute virus infection. Each viral pathogen
has unique, frequently nuanced, aspects to its replication, which affects the host response and as a consequence the capacity
of the virus to produce disease. There are, however, common features to the T cell response to viruses, which produce acute
limited infection. This is true whether virus replication is restricted to a single site, for example, the respiratory tract (RT), CNS
etc., or replication is in multiple sites throughout the body. In describing below the acute T cell response to virus infection, we
employ acute virus infection of the RT as a convenient model to explore this process of virus infection and the host response.
We divide the process into three phases: the induction (initiation) of the response, the expression of antiviral effector activity
resulting in virus elimination, and the resolution of inflammation with restoration of tissue homeostasis.
Lung Dendritic Cells and Control of T Cell Activation
and Initial Differentiation
While the respiratory tract (RT) contains various cell types that
support the productive infection and replication of viral path-
ogens, these cells often provide the first line of defense against
a broad array of common respiratory viral pathogens such
as influenza A virus (IAV), respiratory syncytial virus (RSV),
rhinovirus, and coronaviruses (i.e., severe acute respiratory
syndrome coronavirus (SARS-CoV)) (Table 1). Initially envi-
sioned as a passive barrier between the host and the environ-
ment, the cell types comprising the RT represent an active
robust immune surveillance system. These cells include epithe-
lial cells (e.g., ciliated cells, club cells, goblet cells, and type I
and II alveolar cells), bone marrow origin (CD45þ) innate
immune cells (e.g., alveolar macrophages (AM), natural killer
T (NKT) cells etc.) as well as highly specialized CD45þ profes-
sional antigen-presenting cells (APCs), the dendritic cells
(DCs), which are distributed throughout the conducting
airways, alveoli, and the lung parenchyma (reviewed in Braciale
et al., 2012; Holt et al., 2008; Lambrecht and Hammad, 2012).
DCs are essential for efficient antigen presentation to T cells
and therefore play a pivotal role in initiating the immune
response to foreign antigens (e.g., viral pathogens). They also
serve a companion function in the maintenance of tolerance
to self-antigens. As in other body surfaces (gut and skin), the
lung contains two major types of DCs – conventional DCs
(cDCs) and plasmacytoid DCs (pDCs) (Braciale et al., 2012;
Neyt and Lambrecht, 2013). cDCs are further grouped into
two distinct subsets: (1) cDC1 which further expresses cell
surface markers characteristic of their localization to lymphoid
tissue (i.e., CD8a) or nonlymphoid tissue (i.e., CD103) and
(2) cDC2 which expresses CD11b (CD11bþ cDC) independent
of tissue localization.
Following viral infection of the RT, one of the most impor-
tant functions of cDC is the capture of antigens derived from
the virus for delivery to the site of induction of adaptive
immune responses, the lung-draining lymph node (DLN)
(Lambrecht and Hammad, 2012; Legge and Braciale, 2003;
Lukens et al., 2009; Varga and Braciale, 2013; Figure 1). The
lung-resident DC ‘samples’ the inhaled foreign materials and
pathogens entering the airways. The sampling activity of
cDCs depends primarily on their anatomical distribution
within the lung. CD103þ cDCs are localized mainly at the
basolateral side of the epithelial layer. To sample antigens
they extend dendrites into the lumen of the alveoli and con-
ducting airways. CD11bþ cDCs localize primarily to and
sample the deeper RT sites below the epithelium (i.e., submu-
cosal and interstitial sites) (Neyt and Lambrecht, 2013; Sung
et al., 2006). Following an inflammatory stimulus like virus
infection, these viral antigen-bearing, activated cDCs then leave
the virus-infected lung and emigrate in a CCR7-dependent
manner via the lymphatics to the DLN (Kim and Braciale,
2009; Heer et al., 2008; Figure 1).
Early data supported the concept of a dichotomy among
cDC subsets in driving either CD4 or CD8 T cell differentiation;
thus DC2 (CD11bþ cDC) was considered to be critical for
driving CD4 T cell responses, whereas DC1 (CD8a/CD103þ
cDC) was specialized for induction of CD8þ T cell responses
(del Rio et al., 2007; Dudziak et al., 2007). However, this
view has been challenged by a growing body of recent data
demonstrating that a given cDC subset can trigger both CD4
T and CD8 T cell responses but along different differentiation
and resulting effector pathways. Whereas CD11bþ cDCs prefer-
entially induce CD4þ T differentiation toward the T helper cell
type 2 (Th2) (Plantinga et al., 2013) or T-helper cell type 17
(Th17) (Schlitzer et al., 2013) effector responses, CD103þ
DCs are geared to generate CD4þ T-helper cell type 1 (Th1)
(Furuhashi et al., 2012) or Th2 responses (Nakano et al.,
2012). Likewise, whereas both lung migratory CD103þ and
CD11bþ cDC subsets can serve as primary APCs capable of*These authors have contributed equally to this work.
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Table 1 Common pathogenic viruses infecting the respiratory tract (RT)
Family (genome) Virus Primary target cell in the RT Common symptoms
Paramyxoviridae (, RNA) Respiratory syncytial
virus
Ciliated epithelial cell Bronchiolitis and pneumonia (<2 years and
elderly), colds (elderly)
Measles Epithelial and endothelial cell,
dendritic cell
Fever, coughing, conjunctivitis, runny nose, rash
Human
metapneumovirus
Ciliated epithelial cell Bronchiolitis, pneumonia, colds
Orthomyxoviridae (, RNA) Influenza A/B Epithelial cell, pneumocyte Fever, runny nose, coughing, nasal congestion,
fatigue
Coronaviridae (þ, RNA) SARS-CoV/MERS-CoV Epithelial cell, pneumocyte Severe and often fatal pneumonia
Coronavirus Epithelial cell Common colds, pneumonia
Picornaviridae (þ, RNA) Rhinovirus Epithelial cell Common colds
Adenoviridae (DNA) Adenovirus Epithelial cell Colds, pneumonia, bronchitis
Herpesviridae (DNA) Cytomegalovirus Pneumocyte Congenital damage, glandular fever
(mononucleosis)
Epstein–Barr virus Pneumocyte Glandular fever, fatigue
SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-Cov, middle east respiratory syndrome coronavirus.
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Figure 1 Initiation of T lymphocyte activation and differentiation during respiratory virus infection. Responding to viral infection, CD103þ cDCs
(conventional dendritic cells) and CD11bþ cDCs acquire viral antigens in the lung and migrate from the infected lungs to the regional draining lymph
node (DLN). These lung cDC subsets differ in the expression of peptide displayed on MHC class I, surface expression of costimulatory molecules,
and soluble mediators. Lung CD103þ cDC rapidly accumulates in the DLN and displays a highly potent antigen-presenting cell activity stemming
from the stronger CD8 T cell activation signals which they provide (i.e., greater amounts of signal 1 and 2) to trigger virus-specific T cells. This DC
subset favors the induction of lung-tropic effectors (i.e., interleukin (IL)-2Rahi, Tbethi, and Blimp-1hi), contributing to the elimination of virally infected
cells. A fraction of effectors that has survived after virus clearance may become lung tissue-resident memory T cells. On the other hand, CD11bþ
cDCs display a weaker capacity to activate CD8þ T cells. This favors the programming of naïve CD8 T cells preferentially into activated CD8þ T cells
with memory potential (i.e., Bcl6hi and Eomeshi) that ultimately become circulating central memory cells primarily resident in lymphoid tissues. *CD4
T cells that differentiate into follicular helper subset (Tfh) utilize Bcl6 (and IL-6/21) as a critical regulator of Tfh cell differentiation.
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activating naïve virus-specific CD8þ T cells in the DLN, the
migrant lung CD103þ cDCs in the DLN have been found
during IAV infections to play the primary role in the induction
of the antiviral CD8þ effector T cell responses, that is, the
production of large numbers of activated CD8 T cells with
potent antiviral effector activities (i.e., cytotoxicity and cytokine
production) (Helft et al., 2012; Kim and Braciale, 2009; Mol-
tedo et al., 2011). This may in part be due to the fact that
CD103þ cDCs have the unique ability to capture nonreplicat-
ing viral particles as well as take up apoptotic cells and ‘cross-
present’ apoptotic cell-derived antigens to naïve CD8þ T cells
(Kim and Braciale, 2009; Desch et al., 2011). Further
CD103þ cDCs have superior antigen MHC class I–loading
machinery (Ho et al., 2011) and a higher levels of costimula-
tory molecule expression (e.g., CD24 (Kim et al., 2014))
compared to those of CD11bþ cDCs. CD11bþ cDCs, on the
other hand, support the differentiation of activated CD8þ T
cells into memory cells. These findings suggest a temporal regu-
lation of viral antigen presentation by these two distinct cDC
subsets during immunity to acute viral infections. Indeed
CD103þ DC appears to play a more prominent role as APC
early in viral infection (at least with IAV) resulting in the pref-
erential development of effector CD8þ T cells (critical for
infected cell clearance), whereas CD11bþ DC assumes a more
prominent role later in the infection as APC favoring the forma-
tion of a memory CD8þ T cell response (important for resis-
tance to reinfection) (Ballesteros-Tato et al., 2014, 2010;
Figure 1).
The potential complexity of the initial interactions of naïve
T cells with lung-draining DC within the DLN is further high-
lighted from recent work suggesting that the chronological
age at the time of infection may have profound effects on the
DC usage and therein ultimately the range of effector activity
displayed during the developing T cell response. Early in life,
the distribution of DC subsets in the lungs appears greatly
skewed toward the CD103þ subset. The consequence of this
is evident in animal models, where infection of mice within
the first 2 weeks of life with RSV results in a greater number
of infected DC in the lungs, altered viral antigen uptake and
processing by cDC, a skewing of cDC migrating to the DLNs
to the CD103þ linage, and an overall reduced CD86 and
CD80 expression by these migrant DCs. The overall result in
these changes is a reduced naïve CD8 T cell response to infec-
tion. Similarly, recent findings in SARS-CoV and to a lesser
degree IAV infection suggest that advancing age is associated
with alterations in the response of pulmonary DC to infection
which in turn can reduce CD8 T cell immunity. Prostaglandin
PGD2 levels within the lungs increase with aging and following
infection with certain viruses, for example, SARS-CoV. This
aging and/or SARS-CoV-induced elevated PGD2 expression
inhibits the migration of DC from the lungs to the DLN. In
addition, SARS-CoV reduces MHC II, CD80, and CD86 expres-
sion on DC. As a result there is a profound reduction in DC
activation of a SARS-CoV-specific CD8 T cell response and a cor-
responding delay of viral clearance and increased disease
severity (Channappanavar et al., 2014; Zhao et al., 2011). In
sum, these data would suggest that the timing of the viral infec-
tion (i.e., neonatal vs adult vs aged) may alter the DC and CD8
T cell immune response generated and therein ultimately
control the eventual outcome of the infection.
In addition to the role of DC in the initial activation of
naïve CD8 T cells within the DLN, recent studies have shown
that the effector fate of the developing antiviral effector CD8
T cell is strongly influenced by encountering distinct DC
subsets before egress from the LN to the lungs. Specifically,
during lethal dose inoculums or infection with highly path-
ogenic strains of IAV, pDC within the DLN expresses high
levels of FasL in an interleukin (IL)-12 p40 homodimer-
dependent manner. As the naïve T cells are activated and
begin to upregulate Fas (i.e., the receptor for FasL), the T cells
are killed by the pDC. In this manner, the overall magnitude
of the CD8 T cells found downstream in the lungs is greatly
reduced leading to lack of viral control and eventual death.
Interference with IL-12 p40 homodimer or the FasL:Fas inter-
action prevents the death of the T cells and allows viral
control (Boonnak et al., 2014; Langlois and Legge, 2010;
Legge and Braciale, 2005).
Effector T Cell Responses during Acute Virus Infection
Upon their arrival in the infected lungs, the activated differen-
tiated CD8 and CD4 T cells initiate the effector phase of the T
cell response to acute pulmonary viral infections (Figure 2).
The action of the CD8 cells is usually essential for the elimina-
tion of virus-infected cells and eventual resolution of the infec-
tion. Indeed analyses in experimental models have revealed
that the loss of CD8 T cells during IAV, middle east respiratory
syndrome coronavirus (MERS-CoV), RSV, and SARS-CoV result
in delayed or insufficient viral clearance and in many cases
more severe disease (Bender et al., 1992; Channappanavar
et al., 2014; Epstein et al., 1998; Graham et al., 1991; Thomas
et al., 2006; Topham and Doherty, 1998; Varga and Braciale,
2013; Zhao et al., 2014, 2010, 2009). The effector response
of CD8 T cells can be divided into two primary activities: (1)
functions directed toward the elimination of infected cells,
and (2) production of cytokines and chemokines that will
recruit and direct the responses of additional innate and adap-
tive immune cells as well as contribute to the overall antiviral
state.
The direct elimination of virus-infected cells in the lungs by
antiviral effector CD8 T cells occurs via two mechanisms:
release of lytic granules and engagement of death-inducing
receptors on the cell surface of infected cells by ligands on
the surface of the T cells (Figure 2). Upon immune synapse
formation with the infected cell, the CD8 T cell can release
perforin (a membrane-perturbing molecule) and granzymes
(serine proteases that induce apoptosis) from lytic granules
across the synapse to target the selective elimination of the
infected cell. Further, engagement of the CD8 T cell surface
molecules, FasL and TRAIL, with their ligands, Fas and DR5,
respectively, on the infected cells, triggers the apoptosis of the
infected cells. The importance of each of these effector mole-
cules in CD8 T cell–mediated control of acute respiratory infec-
tions has been well characterized during experimental IAV
infection in mice where the elimination of these effector mole-
cules or their ligands via targeted knockout or blockade reduces
the cytolytic potential of the antiviral T cell response and viral
control (Brincks et al., 2008; Topham et al., 1997). Similar to
IAV infection, deficiency of FasL or perforin during acute RSV
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infections has been shown to delay viral clearance (Aung et al.,
2001; Rutigliano and Graham, 2004).
In addition to the above cytotoxic functions, effector CD8 T
cells, upon recognition of viral antigens, can also produce and
secrete the cytokines, interferon (IFN)g, TNF, IL-2, and IL-10, as
well as chemokines, such as CCL2, CXCL9, and CXCL10. These
chemokines recruit additional immune cells (CD8 as well as
CD4 T cells, DCs, NK cells, monocytes/macrophages) into the
site of infection where they can further modulate the immune
response. The recruited cells can have both positive (i.e., addi-
tional antiviral) as well as negative (i.e., immunopathological)
effects on the control of viral infection and disease severity.
Although IFNg production is a hallmark of the response of
IAV-, MERS-CoV-, RSV-, and SARS-CoV-specific effector CD8
T cells, the impact of IFNg produced by CD8 T cells on viral
replication is likely dependent on the infectious agent. Thus,
in vivo elimination of IFNg during infection by neutralizing
antibody administration or adoptive transfer of IFNg-deficient
CD8 T cells during RSV infection reduces virus control (Ostler
et al., 2002), whereas IFNg-deficient T cell clones are still able
to control IAV infections (Graham et al., 1993). A direct role for
T cell–produced IFNg in virus control is currently less clear
during SARS-CoV and MERS-CoV infections but experiments
have demonstrated that IFNg supplementation during
MERS-CoV and prior to SARS-CoV infection reduces virus titers
suggesting that it may play an important role in viral control
(Zhao et al., 2014, 2012).
In addition to the CD8 T cell mediated influence on other
immune cells within the lung during acute virus infection, it
is now increasingly clear that these cell-to-cell interactions exert
additional bidirectional influences on the phenotype and over-
all health of the CD8 T cells (Figure 2). Although it has long
been appreciated that recognition of signal 1 (i.e., MHC class
I þ virus peptide by TCR) is required for induction of cytotox-
icity, recent studies suggest that signal 2 (costimulation) and
signal 3 (cytokine) interactions have a major influence on the
local lung-specific CD8 T cell response during acute viral
infections. These additional interactions include the long-
appreciated CD4 T cell help and production of IL-2 as a growth
factor but also include recent work demonstrating differential T
cell effector responses and fitness upon interactions with
differing cells types within the lungs. For instance, virus-specific
CD4 T cells produce IL-2 in conjunction with IL-27 produced
by inflammatory mononuclear cells/neutrophils which in
turn supports the production of the anti-inflammatory cyto-
kine IL-10 by IAV-specific CD8 T cells responding to viral
antigen (Sun et al., 2011b). This IL-10 production is critical
in the control of the overall inflammation and protection
Figure 2 Effector T cell responses during acute respiratory virus infection. Upon entry into the inflamed lung after activation in the draining lymph
node, effector T cells undergo additional differentiation and rounds of proliferation regulated by local antigen-presenting cells (APCs) and locally
produced soluble mediators. An array of cytokines and chemokines produced in situ by APC-stimulated effector T cells promote virus clearance via
direct killing mechanisms (i.e., perforin, granzyme, TRAIL, and FasL) or indirect pathways (i.e., cytokines). T cell triggering also allows T cell produc-
tion of chemokines used to recruit additional immune cells into the response. Notably, recruited inflammatory cells (i.e., neutrophils) cooperate with
CD4 and CD8 T effectors to drive the production of regulatory cytokines such as interleukin (IL)-10. Insert: T cell interaction with epithelial cells
engages cytotoxic pathways to mediate direct viral control with minimal production of inflammatory cytokines such as interferon g. DC, dendritic cell;
pDC, plasmacytoid DC; cDC, conventional DC.
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from immunopathology. Interestingly the modulation of CD8
T cell effector ability within the lungs is regulated not just by
the inflammatory milieu but can be specifically tuned by the
cell that the T cell is interacting with at the time. During IAV
infections, CD8 T cell interactions with CD45þ cells expressing
the costimulatory molecules, CD80 and CD86, drive both cyto-
kine and cytolytic effector responses, whereas interaction with
CD45þ cells in the absence of CD80/CD86 interactions or
epithelial cells results in only cytolytic effector ability (Hufford
et al., 2011). Further, effector CD8 T cell interactions with APCs
expressing cognate MHC class I–viral peptide, various costimu-
latory molecules and transpresenting IL-15 have been impli-
cated in providing important antiapoptotic signals to the
effector CD8 T cells allowing them to survive the harsh inflam-
matory environment of the lungs and expand to the levels
required to control the virus infection (Hufford et al., 2012;
McGill et al., 2008, 2010).
It is important to note that although an effector CD8 T cell
response to IAV, RSV, MERS-CoV, and SARS-CoV has been
shown to be critical for viral control, the overall CD8 T cell
effector response during SAR-CoV, unlike IAV and RSV, is
substantially reduced in mice consistent with observations in
humans (Zhao et al., 2011). This is due in part to the above
described effects of SARS-CoV on DC during the induction
phase of the response (i.e., reduced migration, costimulation,
MHC expression). It is, however, worth noting, given the
important role delineated for local APC interactions with the
effector T cells within the lungs described above for IAV (McGill
et al., 2008, 2010), that defective APC function during the
effector phase of the CD8 T cell response (e.g., SAR-CoV infec-
tion) in the lungs may have additional negative effects on the
magnitude of the effector T cell response and consequent
diminished control of virus replication.
Role of T Cells in the Resolution of Pulmonary
Inflammation Following Respiratory Virus Infection
Following the clearance of infectious viruses, the host undergoes
a resolution process to quiet/resolve inflammatory responses in
the RT and to repair the damaged epithelium (Figure 3).
Complete resolution of host inflammation and rapid tissue
repair are crucial for the restoration of normal lung homeostasis
and gas-exchange function (Gorski et al., 2012). Many immune
and structural cell types such as IL-22-producing NK cells,
amphiregulin-expressing innate lymphoid type 2 cells, type 2
macrophages, and tissue stem cells (Gorski et al., 2012; Kumar
et al., 2013a,b; Li et al., 2011; Monticelli et al., 2011; Shirey
et al., 2014; Vaughan et al., 2015; Zuo et al., 2015) are required
for host resolution of infection and lung repair, although when
and how these cells co-opt to do so remain largely undefined. T
cells, including both effector and regulatory T cells (Treg cells),
are an integral component of the cellular machinery required for
resolution of inflammation and tissue recovery following the T
cell response to respiratory virus infection (Braciale et al., 2012;
Sun and Braciale, 2013).
Figure 3 Role of T cells in the resolution of pulmonary inflammation following respiratory virus infection. During and after viral clearance, effector
T cells and Foxp3þ regulatory T cells (Treg cells) infiltrating the infected lung produce regulatory cytokines (i.e., anti-inflammatory interleukin (IL)-10
and anti-inflammatory TGFb) and express suppressive surface molecules (i.e., program death 1 (PD-1) and natural killer group protein 2, member A
(NKG2A)). These immunoregulatory mediators/molecules play a critical role in limiting tissue injury by suppressing the production of proin-
flammatory cytokines produced by the effector T cells and inflammatory innate cells. This balancing act between effector and Treg cells is crucial in
promoting recovery with minimal infection-associated immunopathology in the site of infection. APC, antigen-presenting cell.
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Forkhead box P3 (Foxp3þ) Treg cells accumulate in large
numbers in the RT during the resolution phase of both IAV
and RSV infection (Fulton et al., 2010; Lee et al., 2010; Liu
et al., 2010; Moser et al., 2014; Figure 3). These Treg cells are
largely generated intrathymically and react to viral antigens in
the lung (Bedoya et al., 2013; Liu et al., 2010). These lung
Treg cells also exhibit a unique ‘effector’ phenotype and
produce high levels of anti-inflammatory cytokine IL-10 and
other immune-regulatory molecules including granzyme B
(Bedoya et al., 2013; Cretney et al., 2011; Loebbermann
et al., 2012b), which could enhance the ability of Treg cells
to control pulmonary inflammation following infection. The
local induction of these ‘effector’ Treg cells depends on several
transcription factors including interferon regulatory factor 4
(IRF4), B lymphocyte-induced maturation protein 1 (Blimp1),
and T-box expressed in T cells (T-bet) (Bedoya et al., 2013;
Cretney et al., 2011). Importantly, depletion of Treg cells
results in overactive and persistent tissue inflammation and
delays host recovery from IAV and RSV infection (Fulton
et al., 2010; Lee et al., 2010; Liu et al., 2010; Moser et al.,
2014). Conversely, promotion of the expansion of Treg cells
or transfer of Treg cells into the infected lungs diminishes
exuberant respiratory inflammation and promotes rapid host
recovery from IAV infection (Lee et al., 2010; Sakthivel et al.,
2014). Thus, Treg cells are essential for resolving host inflam-
mation and promoting tissue recovery during acute respiratory
virus infection.
As discussed above, effector T cells are essential for viral
clearance in the RT through their ability to kill virus-infected
cells. However, upon antigenic stimulation, lung effector T cells
also produce large quantities of inflammatory cytokines and
mediators in situ (Hufford et al., 2015), which can promote
host inflammation and cause tissue damage (Braciale et al.,
2012; La Gruta et al., 2007) during both IAV and RSV infection
(La Gruta et al., 2007; Openshaw and Chiu, 2013; Figure 3).
Thus, the production of inflammatory mediators by lung
effector T cells (i.e., T cell inflammatory activities) needs to
be tightly regulated to avoid excess tissue inflammation and
damage following respiratory virus infection. To this end, stim-
ulation of T cell inflammatory activities requires the encounter
of T cell receptor by MHC and peptides derived from viral anti-
gens and costimulatory signals including CD80/86 expressed
on APCs (Hufford et al., 2011, 2015). As the amount of antigen
deposition in the tissue drastically decreases following the
clearance of virus-infected cells, inflammatory activities of the
effector T cells rapidly wane (Hufford et al., 2011, 2015), which
helps to resolve T cell–mediated inflammation. In addition,
effector T cells also bear several regulatory factors to actively
dampen inflammatory responses induced by T cells themselves
or other immune cells (Sun and Braciale, 2013). For example,
lung effector CD4 and CD8 T cells produce high levels of the
regulatory cytokine IL-10 during both IAV and RSV infections
(Loebbermann et al., 2012a; McKinstry et al., 2009; Sun
et al., 2011a,b, 2009; Weiss et al., 2011). As noted above,
blockade of IL-10 function at the time of T cell infiltration to
the lung increases proinflammatory cytokine levels in the RT
and delays host recovery during IAV and RSV infection
(Loebbermann et al., 2012a; Sun et al., 2011a; Sun et al.,
2009; Weiss et al., 2011), suggesting that IL-10 derived
from effector T cells functions to promote the resolution of
pulmonary inflammation and recovery. Notably, certain poly-
morphisms of the IL-10 gene are associated with a higher risk
of severe RSV bronchiolitis, pointing to the possibility that
IL-10 may control the severity of acute respiratory virus infec-
tion in humans (Helminen et al., 2008).
In addition to IL-10, effector T cells in the lung also express
high levels of coinhibitory receptors including program death 1
(PD-1) and natural killer group protein 2, member A (NKG2A)
during IAV and RSV infection (Ely et al., 2014; Erickson et al.,
2012; McNally et al., 2013; Rutigliano et al., 2014; Yao et al.,
2014; Zhou et al., 2008; Figure 3). PD-1 expression on effector
T cells is linked to their functional impairment in the lung and
may delay the clearance of virus infection during IAV and
human metapneumovirus (HMPV) infection (Erickson et al.,
2012; McNally et al., 2013; Rutigliano et al., 2014; Zhou
et al., 2008). On the other hand, the blockade of the interaction
of PD-1 and its ligand PD-L1 results in exaggerated and pro-
longed respiratory inflammation without altering viral
clearance during RSV infection, indicating that this immune-
regulatory mechanism is also important in limiting T cell
inflammatory activities in the lung and contributes to the reso-
lution of tissue inflammation during RSV infection (Yao et al.,
2014). Notably, PD-1 is expressed on T cells in nasal washes of
RSV-infected children (Yao et al., 2014), suggesting that,
similar to mice, PD-1 could likewise function in controlling
respiratory inflammation in humans. In addition to PD-1,
lung effector CD8 T cells express increased levels of NKG2A
as a result of migration from DLN to the inflammatory lung
environment (Ely et al., 2014; Zhou et al., 2008). Similar to
PD-1, NKG2A appears to be important in restricting CD8
T cell effector function and limiting immune-pathology as
the disruption of NKG2A in CD8 T cells or the ablation of
NKG2A ligand in the lung leads to exaggerated pulmonary
inflammation and damage during IAV infection (Ely et al.,
2014; Zhou et al., 2008).
As noted above, effector T cells gain the expression of
important regulatory molecules, including IL-10, PD-1, and
NKG2A, upon migration to the infected lungs from DLN. In
conjunction with this, effector CD8 T cells in the lung also
downregulate their capability to produce IFNg following
antigen stimulation (Arimilli et al., 2008, 2010; Fulton et al.,
2008). Together, although it remains to be determined whether
those tissue effector T cells could pass through a stable and
transmissible differentiation state, these data suggest that the
lung local environment could reshape the differentiation status
of effector T cells to restrict their production of inflammatory
mediators and to promote their expression of anti-
inflammatory factors. Understanding the associated mecha-
nisms regulating the balance and timing of the production of
proinflammatory versus anti-inflammatory mediators may
offer opportunities to promote rapid resolution and recovery
of respiratory virus infection while limiting immune-mediated
disease.
Concluding Remarks
This Encyclopedia article has dealt primarily with the induc-
tion, effector function, and control of inflammation of CD8þ
T cell responses during acute virus infection. Many of the topics
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addressed in this section, for example, T cell activation, costi-
mulation, DC as APC, are dealt with at great depth in other
sections of this Encyclopedia. Likewise, the contribution of
CD4 T cell responses to acute and chronic virus infection are
dealt with in detail in other sections of the Encyclopedia. The
reader is referred to these sections.
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